Exelixis Inc. (NASDAQ: EXEL) reported second-quarter earnings of 29 cents per share, down 6.4% year-over-year. The bottom line surpassed the average analysts’
Exelixis surpasses Q2 earnings estimate by 6 cents
Categories
Biotechnology
Amarin’s stock gains on Q2 results beat
Amarin Corporation plc (NASDAQ: AMRN) reported better-than-expected revenue and earnings for the second quarter of 2019, allowing the stock to gain 2.2%
BioTelemetry Q2 earnings exceed estimates on record revenues; stock up 10%
Medical technology company BioTelemetry, Inc. (NASDAQ: BEAT) reported higher earnings and revenues for the June quarter. Earnings topped expectations, while revenues came
Gilead’s Q2 results beat estimates
Gilead Sciences Inc. (NYSE: GILD) beat market estimates for revenue and earnings in the second quarter of 2019. Shares were down 0.21%
Amgen beats Q2 earnings and revenue estimates
Amgen Inc. (NASDAQ: AMGN) reported second quarter 2019 adjusted EPS of $3.97 on revenue of $5.9 billion. Analysts had predicted the biotechnology
Pfizer’s stock suffers as Q2 results and Mylan deal fail to impress Wall Street
Pfizer Inc.’s (NYSE: PFE) shares continue to trade in red after the company narrowly missed revenue estimates for the second quarter of
Celgene Q2 profit beats estimates, lifts FY19 guidance
Celgene Corporation (NASDAQ: CELG) reported a 50% jump in earnings for the second quarter of 2019 helped by higher revenue as well
Eli Lilly Q2 profit beats estimates, lifts FY19 forecast
Eli Lilly and Company (NYSE: LLY) swung to a profit in the second quarter of 2019 from a loss last year, helped
Earnings preview: What to look for when Gilead reports Q2 results
Gilead Sciences Inc. (NYSE: GILD) is scheduled to report second quarter 2019 earnings results on Tuesday, July 30, after market close. Analysts
AbbVie tops Q2 views; lifts FY19 earnings outlook
AbbVie's (NYSE: ABBV) earnings and revenue for the second quarter of 2019 surpassed Wall Street's estimates. AbbVie reported adjusted EPS of $2.26
Bristol-Myers Q2 earnings, revenue top Street; stock dips on weak guidance
Biopharma company Bristol-Myers Squibb (NYSE: BMY) on Thursday reported higher earnings and revenues for the second quarter, The results also came in
AstraZeneca’s Q2 results beat market expectations
AstraZeneca Plc (NYSE: AZN) topped market estimates for revenue and earnings in the second quarter of 2019, giving shares a lift of
What to expect from AbbVie Q2 earnings
AbbVie (NYSE: ABBV) is scheduled to report its earnings results for the second quarter of 2019 on Friday before the market opens.
Earnings preview: Celgene deal in focus as Bristol-Myers prepares for Q2 results
Bristol-Myers Squibb (NYSE: BMY) will be releasing its quarterly results amid growing skepticism over the planned acquisition of rival drugmaker Celgene (CELG),
Earnings: Alexion Pharma Q2 results top expectations; raises FY19 guidance
Alexion Pharmaceuticals (Nasdaq: ALXN) reported a 28% growth for its second-quarter earnings, helped by an increase in revenues. The results also topped
Is Advaxis exhausting its financial resources with the stock hitting a record low?
Advaxis Inc. (NASDAQ: ADXS) stock plunged to a record low of $1.54 on Tuesday as the late-stage biotech company has returned the
Top biotech stocks to be considered for investment this year
When the massive selloff battered Wall Street in the final months of 2018, biotechnology stocks were no exception. And, most of them
Advaxis’ revenue declines in Q2 as Amgen terminaties collaboration agreement
Advaxis (NASDAQ: ADXS) reported that Q2 revenue decreased to $1.2 million from $1.7 million in the prior year quarter. The 32% decline
Immunogen Inc (NASDAQ: IMGN) Q1 2019 Earnings Call Transcript
Immunogen Inc (IMGN) Q1 2019 earnings call dated May 03, 2019 Corporate Participants: Sarah Kiely -- Director of Investor Relations Mark Enyedy -- President and Chief Executive Officer
Exelixis tops Q1 earnings and revenue estimates
Exelixis Inc. (NASDAQ: EXEL) surpassed Q1 earnings and revenue projections. The company reported earnings of $0.27 per share on revenue of $215.5
Novavax Q1 earnings preview: Future plans on ResVax and NanoFlu will be the key focus points
Novavax Inc (NASDAQ: NVAX) is slated to report its first quarter 2019 earnings results after market closes on Thursday. Novavax stock, which